Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00005921
NCT00005921CompletedNot Applicable

An Open, Serial-Panel, Multiple-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of L-743,872 in Patients With Candida Esophagitis

Merck Sharp & Dohme LLC1 site in 1 country18 target enrollmentStarted: August 31, 2001Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
18
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to see if it is safe to give L-743,872 to men with candidal esophagitis, an AIDS-related yeast infection in the esophagus.

Detailed Description

In this open-label study, patients receive intravenous L-743,872 every 24 hours at one of three dose levels for 14 days. Post-study safety evaluations continue for 4 weeks after the final dose. Pharmacokinetics and safety measurements are taken throughout the 6-week study.

Study Design

Study Type
Interventional
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •You may be eligible for this study if you:
  • •Are an 18- to 65-year-old man with candidal esophagitis.

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 2
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With FluconazoleCandidiasis, OralHIV Infections
NCT00005920Merck Sharp & Dohme LLC70
Completed
Phase 1
Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsHealthy
NCT01737996Boehringer Ingelheim32
Terminated
Phase 1
A Safety Study of LY3462817 and LY3509754 in Participants With PsoriasisPsoriasis
NCT04152382Eli Lilly and Company30
Completed
Phase 3
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaPersistent or Recurrent Cutaneous T-Cell Lymphoma
NCT01871727Eisai Inc.112
Active, not recruiting
Phase 4
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's SyndromeEndogenous Cushing Syndrome
NCT06131580Centre hospitalier de l'Université de Montréal (CHUM)7